Literature DB >> 1997107

Poor prognosis for malignant melanoma in Northern Ireland: a multivariate analysis.

L G Gordon1, W S Lowry, P J Pedlow, C C Patterson.   

Abstract

All cases of cutaneous malignant melanoma, CMM, diagnosed in Northern Ireland between 1974-1978 were reviewed, classified and followed up until the end of 1984. The overall 5 year survival is 54%, among the worst reported in recent literature. Multivariate analysis of these cases confirms some previous findings from other studies, but also reveals features not apparent in univariate analysis. Prognosis worsens with increasing thickness and the presence of ulceration. Likewise histopathological type has an independent effect on survival, ALM having the worst prognosis. Tumour profile emerges as a significant feature affecting prognosis, flat lesions having the poorest outlook, given their thickness. Survival is worse with increasing age. Anatomical site is less important than suggested by previous univariate analysis. Sex has little influence on prognosis when adjusted for the other variables. Cell type and pigmentation are of no prognostic value. Several features including diagnostic delay contribute to the poor overall survival for CMM in Northern Ireland. Educational intervention is essential if this trend is to be reversed.

Entities:  

Mesh:

Year:  1991        PMID: 1997107      PMCID: PMC1971773          DOI: 10.1038/bjc.1991.66

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  10 in total

1.  Missed malignant melanomas.

Authors:  L G Gordon; W S Lowry
Journal:  Br Med J (Clin Res Ed)       Date:  1986-06-07

2.  Reasons for poor prognosis in British patients with cutaneous malignant melanoma.

Authors:  V R Doherty; R M MacKie
Journal:  Br Med J (Clin Res Ed)       Date:  1986-04-12

3.  Health and the ozone layer.

Authors:  R M Mackie; M J Rycroft
Journal:  BMJ       Date:  1988-08-06

4.  Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma.

Authors:  A Breslow
Journal:  Ann Surg       Date:  1970-11       Impact factor: 12.969

5.  Malignant melanoma in Scotland 1979-1983.

Authors:  R M MacKie; J F Smyth; D S Soutar; K C Calman; A C Watson; J A Hunter; K M McLaren; J B MacGillivray; J L McPhie; R Rankin
Journal:  Lancet       Date:  1985-10-19       Impact factor: 79.321

6.  Histologic features of tumors and the female superiority in survival from malignant melanoma.

Authors:  H M Shaw; V J McGovern; G W Milton; G A Farago; W H McCarthy
Journal:  Cancer       Date:  1980-04-01       Impact factor: 6.860

7.  The prognostic significance of ulceration of cutaneous melanoma.

Authors:  C M Balch; J A Wilkerson; T M Murad; S J Soong; A L Ingalls; W A Maddox
Journal:  Cancer       Date:  1980-06-15       Impact factor: 6.860

8.  The regressing thin malignant melanoma: a distinctive lesion with metastatic potential.

Authors:  M A Gromet; W L Epstein; M S Blois
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

9.  The incidence and pathogenesis of invasive cutaneous malignant melanoma in Northern Ireland.

Authors:  L G Gordon; W S Lowry
Journal:  Br J Cancer       Date:  1986-01       Impact factor: 7.640

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

  10 in total
  2 in total

1.  The Evidence Based Medicine approach to diagnostic testing: practicalities and limitations.

Authors:  Robert C Hawkins
Journal:  Clin Biochem Rev       Date:  2005-05

2.  Cutaneous malignant melanoma in Northern Ireland.

Authors:  P J Pedlow; M Y Walsh; C C Patterson; R J Atkinson; W S Lowry
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.